JP2005525355A5 - - Google Patents

Download PDF

Info

Publication number
JP2005525355A5
JP2005525355A5 JP2003570859A JP2003570859A JP2005525355A5 JP 2005525355 A5 JP2005525355 A5 JP 2005525355A5 JP 2003570859 A JP2003570859 A JP 2003570859A JP 2003570859 A JP2003570859 A JP 2003570859A JP 2005525355 A5 JP2005525355 A5 JP 2005525355A5
Authority
JP
Japan
Prior art keywords
composition according
amount
composition
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003570859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525355A (ja
JP4480400B2 (ja
Filing date
Publication date
Priority claimed from GB0204712A external-priority patent/GB2386066A/en
Application filed filed Critical
Publication of JP2005525355A publication Critical patent/JP2005525355A/ja
Publication of JP2005525355A5 publication Critical patent/JP2005525355A5/ja
Application granted granted Critical
Publication of JP4480400B2 publication Critical patent/JP4480400B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003570859A 2002-02-28 2003-02-12 サリチルアニリド化合物、ポリマー成分および少なくとも1種の他の抗寄生虫化合物を含む持続性駆虫組成物 Expired - Lifetime JP4480400B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0204712A GB2386066A (en) 2002-02-28 2002-02-28 Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
PCT/GB2003/000645 WO2003072113A1 (en) 2002-02-28 2003-02-12 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound

Publications (3)

Publication Number Publication Date
JP2005525355A JP2005525355A (ja) 2005-08-25
JP2005525355A5 true JP2005525355A5 (enExample) 2006-04-06
JP4480400B2 JP4480400B2 (ja) 2010-06-16

Family

ID=9931978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003570859A Expired - Lifetime JP4480400B2 (ja) 2002-02-28 2003-02-12 サリチルアニリド化合物、ポリマー成分および少なくとも1種の他の抗寄生虫化合物を含む持続性駆虫組成物

Country Status (23)

Country Link
US (1) US9289380B2 (enExample)
EP (1) EP1478372B1 (enExample)
JP (1) JP4480400B2 (enExample)
AP (1) AP1977A (enExample)
AR (1) AR038852A1 (enExample)
AT (1) ATE347897T1 (enExample)
AU (1) AU2003205887B2 (enExample)
BR (1) BR0307974B1 (enExample)
CA (1) CA2476520C (enExample)
CO (1) CO5611154A2 (enExample)
CR (1) CR7429A (enExample)
CY (1) CY1107530T1 (enExample)
DE (1) DE60310377T2 (enExample)
DK (1) DK1478372T3 (enExample)
EC (1) ECSP045320A (enExample)
ES (1) ES2275076T3 (enExample)
GB (1) GB2386066A (enExample)
MX (1) MXPA04007996A (enExample)
NZ (1) NZ534704A (enExample)
PT (1) PT1478372E (enExample)
SI (1) SI1478372T1 (enExample)
WO (1) WO2003072113A1 (enExample)
ZA (1) ZA200406782B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002952597A0 (en) * 2002-11-11 2002-11-28 Schering-Plough Pty. Limited Topical parasiticide formulations and methods of treatment
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1610765B1 (en) 2003-03-31 2008-08-13 ALZA Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
US7666444B2 (en) 2004-02-02 2010-02-23 Wyeth Antiparasitic composition
EP1824474A1 (en) * 2004-12-10 2007-08-29 Bayer HealthCare AG Anthelmintic composition
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
NO2462246T3 (enExample) 2009-09-28 2018-02-03
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
FR2991173B1 (fr) 2012-06-04 2015-11-06 Virbac Composition veterinaire a administration cutanee a base d'oxyclozanide
US10350196B2 (en) 2013-09-30 2019-07-16 Zoetis Services Llc Long-acting spiro-isoxazoline formulations
PL3010511T3 (pl) 2014-09-12 2018-07-31 Antibiotx A/S Przeciwbakteryjne zastosowanie halogenowanych salicylanilidów
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
GB201604484D0 (en) * 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
TWI754643B (zh) 2016-05-16 2022-02-11 美商因塔希亞治療公司 升糖素受體選擇性多肽和彼之使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
DE2263509C2 (de) 1972-12-27 1981-12-24 Rudolf Dr. 6380 Bad Homburg Kürner Deodorant
US4005218A (en) 1975-03-18 1977-01-25 Janssen Pharmaceutica N.V. Antiparasitic salicylanilide derivatives
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4206205A (en) 1977-10-03 1980-06-03 Merck & Co., Inc. Monosaccharide and aglycone derivatives of C-076
US4171314A (en) 1977-12-19 1979-10-16 Merck & Co., Inc. 13-Halo and 13-deoxy C-076 compounds
US4173571A (en) 1977-12-19 1979-11-06 Merck & Co., Inc. 13-Halo and 13-deoxy derivatives of C-076 compounds
US4128632A (en) * 1978-02-13 1978-12-05 Merck & Co., Inc. Solubilization of Rafoxanide
NZ197796A (en) 1980-08-04 1984-11-09 Merck & Co Inc Stabilised aqueous formulations containing ivermectin
NZ210505A (en) 1983-12-22 1988-06-30 Merck & Co Inc Parasiticidal compositions containing avermectin or milbemycin derivatives
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
NZ223200A (en) * 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
US5273805A (en) * 1991-08-05 1993-12-28 Minnesota Mining And Manufacturing Company Structured flexible carrier web with recess areas bearing a layer of silicone on predetermined surfaces
NZ335166A (en) 1999-04-14 2001-11-30 Ashmont Holdings Ltd Anthelmintic composition containing triclabendazole in at least one solvent
CN1054504C (zh) * 1993-03-15 2000-07-19 科尔加特·帕尔莫利弗公司 洁牙剂
PL174488B1 (pl) 1993-05-10 1998-08-31 Merck & Co Inc Preparat do zwalczania pasożytów zwierząt oraz sposób wytwarzania preparatu do zwalczania pasożytów zwierząt
EP0710105B1 (en) 1993-06-15 2003-07-30 The Australian National University Synergistic anthelmintic compositions against fasciola hepatica and other fasciola species
NZ248486A (en) * 1993-08-24 1996-07-26 Ashmont Holdings Limited Subst Stable anthelmintic formulation containing closantel and one or more avermectins or milbemycins in a glycol based solvent
WO1995016447A1 (en) * 1993-12-13 1995-06-22 Michael Hilary Burke Anthelmintic composition containing rafoxanide and fenbendazole
FR2739778B1 (fr) * 1995-10-13 1997-12-12 Virbac Lab Formulation topique destinee a traiter la maladie de la douve du foie chez l'animal
US5773422A (en) * 1996-01-29 1998-06-30 Komer; Gene Avermectin formulation
US6193989B1 (en) * 1997-03-21 2001-02-27 Biogenesis S.A. Long acting injectable parasiticidal composition and the process for its preparation
US6340672B1 (en) 2000-02-16 2002-01-22 Phoenix Scientific, Inc. Parasiticidal formulation and a method of making this formulation
AUPQ875700A0 (en) 2000-07-13 2000-08-03 Reflex Research Limited Combination compositions
AUPR510001A0 (en) * 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method

Similar Documents

Publication Publication Date Title
JP2005525355A5 (enExample)
US8658201B2 (en) Rapidly dissolving film for delivery of an active agent
WO2005000265A3 (en) Gel-stabilized nanoparticulate active agent compositions
CA2594215A1 (en) Sustained-release nanoparticle compositions and methods for using the same
RU2002135623A (ru) Рецептура на основе гепарина, глюкозаминогликана или гепариноида и применение рецептуры и ее основы
PT1210934E (pt) Preparação de transportador farmacêutico aplicável a superfícies de mucosas
RS20120201A3 (en) METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C
JP2005524730A5 (enExample)
NO20011639L (no) Bionedbrytbare triblokk-kopolymerer av polyester- polyetylenglykol med lav molekylvekt og med reversible termiskegelingsegenskaper
CO5611154A2 (es) Composicion antiparasitaria de accion prolongada que contienen un compuesto de salicilanilida, una especie polimerica y por lo menos otro compuesto antiparasitario
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
PT910339E (pt) Aerossol polar bucal
BR9908121A (pt) Forma galênica de liberação imediata e de liberação prolongada administrável por via oral compreendendo um agente estimulador de absorção e utilização deste agente estimulador de absorção
TR200101088T2 (tr) Sürekli salınımlı farmasötik kompozisyon ve farmasötik olarak aktif ajanın salınma metodu
WO2004034975A3 (en) Sustained release profile modification
JP2005538045A5 (enExample)
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
DK1441769T3 (da) Farmaceutiske formuleringer, der indeholder lave koncentrationer af peroxid, til behandling eller forebyggelse af vaginale infektioner
WO2002064132A3 (en) Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
RU2007113156A (ru) Твердая нанокомпозиция для доставки биологически активных веществ
WO2005107773A3 (en) Solid dosage form of wetted heparin
WO2002028362A3 (fr) Composition vaccinale et procede de stabilisation
EA200600237A1 (ru) Антипаразитарная композиция
JP2003160735A5 (enExample)
DE60205726D1 (de) Telomere einschliessende polymerzusammensetzungen und artikel oder teile daraus